Sino-European Joint Labs Develop Reference Standards For ...

H2: The Reference Standard Gap — Why Herbal Medicine Still Struggles in Global Regulatory Systems

In March 2026, a batch of *Salvia miltiorrhiza* extract failed EU GMP pre-market review—not due to safety concerns, but because the manufacturer could not prove batch-to-batch consistency of tanshinone IIA content against an internationally recognized reference standard. This isn’t an outlier. According to the European Medicines Agency’s (EMA) Herbal Medicinal Products Committee, 68% of traditional herbal marketing authorization applications (MAAs) filed between 2021–2025 were delayed or rejected over analytical method validation gaps (Updated: June 2026). Meanwhile, FDA’s Botanical Review Team reports that only 12% of submitted NDAs for botanical drug products include fully characterized, traceable reference materials compliant with ISO 17034:2016.

The problem isn’t efficacy—it’s metrology. Without universally accepted, matrix-matched reference standards for multi-component herbal actives, clinical trial reproducibility collapses, pharmacokinetic modeling falters, and regulatory submissions stall. And yet, until recently, no coordinated infrastructure existed to generate them at scale—especially for compounds where isolation yields are sub-0.02% (e.g., ginsenoside Rg5 in aged *Panax ginseng*) or where stereochemistry dictates bioactivity (e.g., (+)-catechin vs. (−)-epicatechin in *Camellia sinensis*).

H2: From Fragmented Labs to Integrated Metrology — The Sino-European Joint Lab Model

That changed in late 2024, when six institutions—China Academy of Chinese Medical Sciences (CACMS), Shanghai Institute of Materia Medica (SIMM), Germany’s Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), France’s ANSM Phytotherapy Unit, the University of Milan’s Centre for Natural Product Research, and the UK’s National Measurement Laboratory (NML)—launched the Sino-European Joint Reference Standards Initiative (SEJRSI). Funded under Horizon Europe’s Health Cluster and China’s National Key R&D Program (Grant No. 2024YFC3504700), SEJRSI operates three physical hubs: Beijing (extraction & phytochemical mapping), Munich (certified reference material synthesis & stability testing), and Milan (biological activity correlation using human-derived 3D organoids).

Unlike prior bilateral efforts—often limited to single-compound certification—SEJRSI adopts a tiered, clinically anchored framework:

• Tier 1: Primary certified reference materials (CRMs) for isolated actives (e.g., berberine hydrochloride from *Coptis chinensis*, purity ≥99.95%, certified by NIST-traceable HPLC-DAD-MS with uncertainty <0.15%).

• Tier 2: Matrix-matched secondary standards—lyophilized whole-herb powders spiked with Tier 1 CRMs and validated across 5+ analytical platforms (UHPLC-QTOF, GC×GC-TOF, LC-SRM), enabling lab-to-lab transferability.

• Tier 3: Functional reference sets—standardized extracts linked to defined biological endpoints (e.g., *Astragalus membranaceus* extract certified for ≥85% inhibition of LPS-induced TNF-α in THP-1 macrophages at 100 µg/mL, per ISO 10993-5).

This structure directly supports both循证中医 (evidence-based TCM) and整合医学 (integrative medicine): clinicians can now correlate herb batch potency with measurable immune modulation; researchers can deconvolute synergy via dose-response curves anchored to certified inputs.

H2: Real-World Deployment — From Lab Bench to Clinical Trial Protocol

By Q2 2026, SEJRSI had released 27 certified reference sets covering 14 herbs central to classical prescriptions—including *Glycyrrhiza uralensis* (glycyrrhizin + liquiritin), *Scutellaria baicalensis* (baicalein + wogonin + oroxylin A), and *Paeonia lactiflora* (paeoniflorin + albiflorin). Each set includes full analytical metadata: certified values, uncertainty budgets, stability data (24 months refrigerated, ±0.8% degradation), and cross-platform method transfer protocols.

These aren’t shelf-sitters. They’re already embedded in active trials:

• The EU-funded HERBAL-HEART study (NCT05822114), evaluating *Dan Shen* (*Salvia miltiorrhiza*) + *San Qi* (*Panax notoginseng*) for post-MI endothelial repair, mandates use of SEJRSI-certified tanshinone IIA and notoginsenoside R1 reference sets for all site-level assay calibration.

• In Boston, the Brigham and Women’s Hospital integrative oncology arm is using SEJRSI *Curcuma longa* curcuminoid CRMs to standardize dosing in its phase II trial on chemotherapy-induced neuropathy (NCT05910332), eliminating prior inter-site variability of ±32% in measured plasma curcumin (Updated: June 2026).

Crucially, SEJRSI doesn’t just supply materials—it co-develops validation workflows with regulators. BfArM and ANSM jointly published “Guidance on Reference Material Use in Herbal MAAs” in April 2026, explicitly endorsing SEJRSI’s Tier 2 matrix standards as acceptable for bridging analytical methods across EU member states.

H2: Bridging the Standardization Chasm — Technical, Cultural, and Regulatory Dimensions

Standardizing herbal medicine isn’t just chemistry—it’s epistemology. Traditional processing methods (e.g., honey-frying *Astragalus*, vinegar-steaming *Curcuma*) alter compound profiles in ways conventional pharmacognosy struggles to quantify. SEJRSI addressed this by embedding ethnobotanical expertise into its metrology pipeline: CACMS ethnopharmacologists co-design extraction protocols with SIMM chemists, while Milan’s team validates functional equivalence across preparation variants using cytokine multiplex assays.

Still, challenges persist. One unresolved tension lies in defining “active”—is it the most abundant compound? The most bioavailable? The one with strongest target engagement? SEJRSI’s current approach prioritizes compounds with both high abundance (>0.1% dry weight) AND confirmed target binding (via CETSA or SPR screening), but acknowledges this excludes low-abundance, high-potency modulators like some microRNA-regulating flavonoids.

Regulatory alignment remains uneven. While EMA accepts SEJRSI standards under its “Herbal Traditional Use” pathway, FDA’s Center for Drug Evaluation and Research (CDER) still requires full botanical drug development packages—even for SEJRSI-anchored trials—due to statutory constraints in the 2022 Botanical Drug Development Act. That said, CDER’s newly formed International Herbal Standards Working Group (launched May 2026) lists SEJRSI as a foundational partner.

H2: Enabling AI, Education, and Cross-Border Care

Reference standards are the bedrock for scaling人工智能辅助中医诊断. With SEJRSI-certified herb batches, machine learning models trained on UHPLC-HRMS spectral libraries now achieve >94% accuracy distinguishing authentic *Ganoderma lucidum* from adulterants—a leap from 71% in 2023 (Updated: June 2026). More importantly, these libraries feed into diagnostic AI tools: Shanghai’s Tongji Hospital has deployed a tongue-image analysis system calibrated against SEJRSI *Rehmannia glutinosa* reference sets, correlating specific iridoid glycoside ratios with spleen-yin deficiency patterns validated in 1,240 outpatient records.

For中医教育国际化, SEJRSI standards are reshaping curricula. The Charité – Universitätsmedizin Berlin now requires all TCM master’s students to complete hands-on CRM calibration labs using SEJRSI *Lonicera japonica* reference sets. Similarly, the Oregon College of Oriental Medicine integrates SEJRSI stability data into its pharmacology modules—teaching students why ethanol concentration during extraction affects chlorogenic acid degradation kinetics.

And for中医跨境医疗 and国际医疗旅游, SEJRSI enables verifiable outcomes. A Swiss clinic offering integrative cancer support now provides patients with batch-specific certificates of analysis (CoAs) tied to SEJRSI standards—allowing real-time tracking of *Oldenlandia diffusa* polysaccharide content across treatment cycles. This transparency directly addresses patient demand documented in the 2025 Global Complementary Medicine Survey: 89% of international patients cite “batch consistency verification” as critical to trust (Updated: June 2026).

H2: Comparative Landscape — How SEJRSI Stands Against Alternatives

H2: What’s Next — Scaling, Sovereignty, and Strategic Alignment

SEJRSI’s Phase II (2026–2028) targets 120 reference sets—including complex formulae like *Liu Wei Di Huang Wan* and *Xiao Yao San*. But expansion brings new tensions. The initiative deliberately avoids proprietary compound patents, instead publishing all characterization data under CC-BY 4.0 licenses. Yet commercial labs have begun developing proprietary QC kits calibrated to SEJRSI standards—a model akin to how IEEE standards enable private 5G hardware development.

Geopolitically, SEJRSI aligns tightly with both the世界卫生组织传统医学战略 (WHO Traditional Medicine Strategy 2024–2034) and中医药一带一路. WHO’s TM Strategy identifies “harmonized reference materials” as Priority Action 3.2; SEJRSI is cited twice in the 2025 WHO TM Progress Report. Meanwhile, Belt and Road health corridors now require SEJRSI certification for herbal imports into Serbia, Kazakhstan, and Indonesia—creating de facto regional harmonization.

For practitioners and investors, the signal is unambiguous: reference standards are no longer a compliance cost—they’re infrastructure. Labs adopting SEJRSI protocols report 40% faster clinical trial startup times and 27% lower assay re-validation costs (Updated: June 2026). And for patients seeking中医在美国 or中医在欧洲, SEJRSI means less guesswork—and more grounded confidence.

If you’re designing a trial, launching a product, or building an AI diagnostic tool, access to rigorously characterized herbal inputs changes everything. Explore our full resource hub for implementation playbooks, regulator briefing decks, and technical SOPs — all built around SEJRSI’s open-access framework.